Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AVNS 
Avanos Medical Inc (AVNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: AVNS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.5% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 570.19M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 1.14 | 52 Weeks Range 11.68 - 25.36 | Updated Date 07/9/2025 |
52 Weeks Range 11.68 - 25.36 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -55.8% | Operating Margin (TTM) 6.15% |
Management Effectiveness
Return on Assets (TTM) 2.26% | Return on Equity (TTM) -36.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 611776074 | Price to Sales(TTM) 0.83 |
Enterprise Value 611776074 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 0.89 | Enterprise Value to EBITDA 17.17 | Shares Outstanding 46244000 | Shares Floating 45368581 |
Shares Outstanding 46244000 | Shares Floating 45368581 | ||
Percent Insiders 3.8 | Percent Institutions 96.13 |
Upturn AI SWOT
Avanos Medical Inc
Company Overview
History and Background
Avanos Medical, Inc. was formerly part of Kimberly-Clark Corporation's healthcare business. It was spun off as an independent company in November 2014. Its roots trace back to the early 20th century through predecessor companies involved in medical devices and technologies.
Core Business Areas
- Chronic Care: This segment develops, manufactures, and markets medical devices for pain management, respiratory health, and digestive health.
- Acute Pain: This segment offers non-opioid pain management solutions, focused on regional anesthesia and acute pain therapies.
Leadership and Structure
Joe Woody serves as the Chief Executive Officer. The company operates with a functional organizational structure, divided into segments based on product categories and support functions like R&D, Sales, and Marketing.
Top Products and Market Share
Key Offerings
- COOLIEF* Cooled Radiofrequency: A minimally invasive pain management solution targeting chronic pain. Competitors include Halyard Health (acquired by Owens & Minor), Medtronic. Market share is variable depending on specific indications and regions, but Avanos is a key player in cooled RF. Specific revenue figures are not publicly broken down.
- ON-Q* Pain Relief System: A non-opioid pain relief system that delivers local anesthetic. Competitors include Pacira BioSciences (EXPAREL). Specific revenue figures are not publicly available.
- MIC-KEY* Feeding Tubes: Gastrostomy tubes used for enteral feeding. Competitors include Applied Medical Technology, Boston Scientific. Revenue figures and market share are not publicly broken down.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulation, and consolidation. Growing demand for minimally invasive procedures and non-opioid pain management options drives market growth. Technological advancements and increasing aging populations fuel demand for advanced medical technologies.
Positioning
Avanos is positioned as a provider of minimally invasive pain management and chronic care solutions. Its competitive advantage lies in its portfolio of non-opioid pain management therapies and established presence in specific market niches.
Total Addressable Market (TAM)
The global pain management devices market is estimated to reach USD 6.3 Billion by 2033. Avanos Medical Inc. has a strong presence in this market. The global enteral feeding devices market is estimated to reach USD 4.44 billion by 2031.
Upturn SWOT Analysis
Strengths
- Focus on minimally invasive and non-opioid solutions
- Established brand recognition in specific product categories
- Strong relationships with healthcare providers
- Diversified product portfolio across chronic and acute care
Weaknesses
- Reliance on a limited number of key products
- Exposure to regulatory changes and reimbursement pressures
- Competition from larger medical device companies
- Potential impact of product recalls or liability claims
Opportunities
- Expansion into new geographic markets
- Development of innovative products and technologies
- Strategic acquisitions to broaden product portfolio
- Increased adoption of non-opioid pain management therapies
Threats
- Intense competition from established players
- Technological obsolescence
- Economic downturns impacting healthcare spending
- Unfavorable regulatory changes or pricing pressures
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Boston Scientific (BSX)
- Pacira BioSciences (PCRX)
- Owens & Minor (OMI)
Competitive Landscape
Avanos faces competition from larger medical device companies with greater resources. Avanos's advantage lies in its specialized products and focus on specific market niches. Success requires continuous innovation and strong execution.
Major Acquisitions
Bard Site Rite Vision Technology
- Year: 2017
- Acquisition Price (USD millions): 80
- Strategic Rationale: Expanded vascular access offerings.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by organic sales growth and acquisitions. Growth rates vary depending on economic conditions and market trends.
Future Projections: Future growth projections depend on analyst estimates and company guidance. Projections are subject to change based on market conditions.
Recent Initiatives: Recent strategic initiatives include product launches, acquisitions, and cost-reduction programs.
Summary
Avanos Medical operates in a competitive medical device market, focusing on pain management and chronic care. They have a diversified product portfolio and are focused on non-opioid solutions. Their smaller size compared to larger competitors necessitates consistent innovation and strategic acquisitions to sustain growth. The company's success depends on navigating regulatory landscapes and demonstrating clinical value for their offerings. Avanos needs to watch out for larger companies encroaching on its specialized markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Avanos Medical Inc. Investor Relations
- Company SEC Filings (10-K, 10-Q)
- Industry Reports (e.g., Market Research Reports)
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avanos Medical Inc
Exchange NYSE | Headquaters Alpharetta, GA, United States | ||
IPO Launch date 2014-10-21 | CEO - | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2227 | Website https://avanos.com |
Full time employees 2227 | Website https://avanos.com | ||
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.